SIRFLOX研究的见解。

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2016-08-01 Epub Date: 2016-05-12 DOI:10.2217/hep-2016-0006

Peter Gibbs

{"title":"SIRFLOX研究的见解。","authors":"Peter Gibbs","doi":"10.2217/hep-2016-0006","DOIUrl":null,"url":null,"abstract":"Peter Gibbs speaks to Laura Dormer, Editorial Director: Peter Gibbs is a medical oncologist at the Western and Royal Melbourne Western Hospitals (Australia), and a laboratory head at the Walter and Eliza Hall Institute (Australia). He has a particular interest in translational research related to prognostic and predictive biomarkers for colorectal cancer. He is also heavily involved in clinical research, including being lead investigator of multiple international Phase III trials. He leads several national and international cancer registries, capturing comprehensive treatment and outcome data for patients treated in routine clinical care.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 3","pages":"191-192"},"PeriodicalIF":1.2000,"publicationDate":"2016-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0006","citationCount":"0","resultStr":"{\"title\":\"Insights into the SIRFLOX study.\",\"authors\":\"Peter Gibbs\",\"doi\":\"10.2217/hep-2016-0006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Peter Gibbs speaks to Laura Dormer, Editorial Director: Peter Gibbs is a medical oncologist at the Western and Royal Melbourne Western Hospitals (Australia), and a laboratory head at the Walter and Eliza Hall Institute (Australia). He has a particular interest in translational research related to prognostic and predictive biomarkers for colorectal cancer. He is also heavily involved in clinical research, including being lead investigator of multiple international Phase III trials. He leads several national and international cancer registries, capturing comprehensive treatment and outcome data for patients treated in routine clinical care.\",\"PeriodicalId\":44854,\"journal\":{\"name\":\"Hepatic Oncology\",\"volume\":\"3 3\",\"pages\":\"191-192\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2016-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/hep-2016-0006\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/hep-2016-0006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/5/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2016-0006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/5/12 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Peter Gibbs是Western和Royal Melbourne Western医院(澳大利亚)的医学肿瘤学家，也是Walter and Eliza Hall Institute(澳大利亚)的实验室主任。他对结直肠癌预后和预测性生物标志物的转化研究特别感兴趣。他还积极参与临床研究，包括担任多个国际III期试验的首席研究员。他领导了几个国家和国际癌症登记处，为在常规临床护理中接受治疗的患者获取综合治疗和结果数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Insights into the SIRFLOX study.

Peter Gibbs speaks to Laura Dormer, Editorial Director: Peter Gibbs is a medical oncologist at the Western and Royal Melbourne Western Hospitals (Australia), and a laboratory head at the Walter and Eliza Hall Institute (Australia). He has a particular interest in translational research related to prognostic and predictive biomarkers for colorectal cancer. He is also heavily involved in clinical research, including being lead investigator of multiple international Phase III trials. He leads several national and international cancer registries, capturing comprehensive treatment and outcome data for patients treated in routine clinical care.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.